Pain Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel drugs. REMOXY The company’s primary drug candidate, REMOXY, is an extended-release oral formulation of oxycodone for the management of moderate-to-severe pain when a continuous, opioid analgesic is needed for an extended period of time. REMOXY is a novel controlled-release oral capsule form of oxycodone in a highly viscous liquid formulation matrix that includes novel excipients. It is primarily formulated to help address issues of abuse and misuse of time-release oxycodone tablets. The company designed REMOXY to discourage common methods of tampering and misuse. Abuse-Resistant Formulation of Hydromorphone The abuse-resistant technology used in REMOXY is applicable to the company’s abuse-resistant formulation of hydromorphone, which is intended to meet the needs of physicians who appropriately prescribe hydromorphone and who seek to minimize the risks of drug diversion, abuse or accidental patient misuse, as well as the needs of pharmacists and the managed care healthcare system in the United States. An investigational new drug (IND), application for the company ‘abuse-resistant formulation of hydromorphone is in place with the U.S. Food and Drug Administration. The company owns all commercial rights with respect to this drug candidate. FENROCK FENROCK is a proprietary abuse-deterrent transdermal pain patch in the pre-IND stage of development. The company owns all product rights worldwide without royalty, milestone or other economic obligations to any third-party. Early-Stage Product Candidates The company continues to develop early-stage novel product candidates. It owns all commercial rights to these early-stage product candidates. Strategy The key elements of the company’s strategy are to focus on clinical development stage products; retain significant rights to its drugs; outsource key functions; and pursue in-licensing or acquisition opportunities. Intellectual Property The company owns or licenses various U.S. and foreign patents, patent applications and rights to patents covering its products and technology. Its material patents and the material patents the company licenses from third parties include the following issued U.S. Patents: 8,420,120; 8,415,401; 8,354,124; 8,168,217; 8,153,152; 8,147,870; 8,133,507; 7,833,543; 6,413,536; 5,968,542; and 5,747,058. The company’s issued U.S. patents and the issued U.S. patents it licenses from third parties for REMOXY are estimated to expire by 2031. In Europe, the granted patents for REMOXY are estimated to expire by 2028. Agreements The company has an exclusive, worldwide development and license agreement with Durect Corporation to use a patented technology that forms the basis for certain drug candidates, including REMOXY. Trademarks REMOXY and FENROCK are trademarks of the company. History Pain Therapeutics, Inc. was founded in 1998. The company was incorporated in Delaware in 1998.
pain therapeutics inc
(PTIE:Consolidated Issue Listed on NASDAQ Global Select )
7801 North Capital of Texas Highway
Austin, TX 78731
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for PTIE.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact PAIN THERAPEUTICS INC, please visit www.paintrials.com. Company data is provided by Capital IQ. Please use this form to report any data issues.